Report : Viral Vector & Plasmid DNA Manufacturing Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product (Viral Vectors, Non-viral Vectors); Application (Cancer, Inherited Disorders, Viral Infections, Others), and Geography
Viral Vector Segment by Product is Expected to Grow at a Faster Pace During Forecast Period
According to The Insight Partners market research study of ‘Viral Vector & Plasmid DNA Manufacturing Market to 2027 – Global Analysis and Forecast by Product, and Application,’ the global Viral Vector & Plasmid DNA Manufacturing market is expected to reach US$ 2,247.7million by 2027 from US$ 459.4million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. The report highlights trends prevailing in the global viral vector & plasmid DNA manufacturing market and the factors driving market along with those that act as hindrances.
Based on Product, the global viral vector & plasmid DNA manufacturing market is segmented into viral vectors and non-viral vectors. The viral vectors segment held the largest share of the market in 2019owing to the rising preference for viral vectors in gene transfer is evident by the increase in number of clinical trials on viral vector-mediated gene therapy and rising in number of initiative taken by market players. Moreover, effective gene delivery, high transfection efficiency, and stable gene expression have made viral vectors a preferred choice for gene transfer. For instance, in 2019, around 372 clinical trials were registered that involved vector-mediated gene therapy production.
The viral vector & plasmid DNA manufacturing market is expected to grow owing to factors such as growing awareness of gene therapy and increasing prevalence of genetic disorders and infectious diseases across the world. Additionally, growth of the global healthcare market is likely to have a positive impact on the market in the coming years.
Brammer Bio, Sanofi, Cardinal Health Inc., FUJIFILM Diosynth Biotechnologies, Cell and Gene Therapy Catapult, Cobra Biologics, FinVector, Kaneka Eurogentec S.A., MassBiologics, Spark Therapeutics, and Uniqure are among the leading companies operating in the viral vector & plasmid DNA manufacturing market.
The report segments global viral vector & plasmid DNA manufacturing market as follows: